Ensysce Biosciences (ENSC) Projected to Post Quarterly Earnings on Monday

Ensysce Biosciences (NASDAQ:ENSC) is anticipated to release its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.99) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Ensysce Biosciences Trading Up 1.5%

Ensysce Biosciences stock opened at $0.55 on Friday. The stock has a market cap of $1.99 million, a P/E ratio of -0.09 and a beta of 1.14. The company has a 50-day moving average price of $0.70 and a 200 day moving average price of $1.52. Ensysce Biosciences has a 12-month low of $0.31 and a 12-month high of $5.20.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Trading of Ensysce Biosciences

Institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its holdings in Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after buying an additional 75,000 shares during the period. DRW Securities LLC grew its stake in Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after buying an additional 29,336 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Ensysce Biosciences in the third quarter worth $34,000. Finally, Virtu Financial LLC purchased a new position in shares of Ensysce Biosciences in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.